Safety of paclitaxel in a patient with ovarian cancer and hyperbilirubinemia due to Rotor's syndrome.

Argon A., Aydiner A., Tas F., Saip P., Topuz E.

Gynecologic oncology, cilt.85, sa.2, ss.362-4, 2002 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 85 Sayı: 2
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1006/gyno.2002.6608
  • Dergi Adı: Gynecologic oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.362-4
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background. Rotor's syndrome is a rare congenital disorder characterized by functional hyperbilirubinemia. Treatment decision may be challenging in a cancer patient with Rotor's syndrome, since the majority of the antineoplastic agents are metabolized in the liver and excreted via the biliary system. We report the first case of paclitaxel administration in a patient with ovarian cancer and elevated bilirubin levels due to Rotor's syndrome.